News & Updates

Treatment with isotretinoin for acne in adolescents does not appear to exert a negative effect on adult height, as reported in a study.

Taking ixekizumab and tirzepatide together results in higher rates of skin clearance and weight loss compared with ixekizumab alone in patients with psoriasis and overweight or obesity, who represent a population that is difficult to treat, according to the phase IIIb TOGETHER-PsO trial.

Many routine baseline screening and monitoring tests show no clear benefit to psoriasis patients prescribed biologic treatments, according to a study.

Treatment with vixarelimab yields clinically meaningful improvements in prurigo nodularis (PN) symptoms, while having a favourable safety profile, according to a phase 2b study.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense pruritus, recurrent eczema, and substantial impairment in quality of life (QoL). Affecting up to 20 percent of children and approximately 10 percent of adults in high-income countries, AD places a significant burden on patients and their families, impacting sleep, productivity, and psychosocial well-being. [Br J Dermatol 2021;184:304-309]

New drug applications approved by US FDA as of 16-31 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A review of literature presented at AAD 2026 reveals an association between hijab wearing and unique hair and scalp disorders.